Please login to the form below

Not currently logged in
Email:
Password:

Paolo Casati named as general manager of Santen Italy

Has over 30 years of experience in the sector

Eye care specialist Santen Pharma has appointed Paolo Casati as general manager of its Italian subsidiary.

Casati brings 30 years of management and global business leadership experience in the ophthalmic sector to the role.

From 2012 to 2014, he served as head of sales force effectiveness at Alcon, an eye care specialist that develops and manufactures medicines and devices for eye care needs.

Prior to that, Casati held a number of senior leadership positions at the firm in sales and marketing departments.

Commenting on his appointment, he said: “Santen group is successful thanks to its commitment to the protection and improvement of eyesight and the quality of life of patients.

“I am very excited to join the team to establish Santen Italy as one of the major companies of reference for the ophthalmic world in Italy.”

Highlights of Casati's career include the creation of the EMEA training organisation at Alcon that covers all business units, technical, sales, management and marketing skills.

Masamichi Sato, head of Santen European group and president of Santen holdings, added: “Our expansion in Italy is an important step in achieving global presence in Europe. Paolo Casati's appointment will bring leadership that fits very well with the company's ambition and values.”

11th December 2014

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

We love what we do and we think it shows.It shows in the work we do, the space we work...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics